Ionis, Novartis' key experimental heart drug fails in late-stage trial

Ionis Pharmaceuticals and Novartis’ late-stage trial of an experimental drug designed to lower high levels of a cholesterol-carrying particle in heart patients failed. The result is a clear setback for the program’s clinical and commercialization outlook and likely pressures near-term valuation and investor expectations for both companies.